Clinical trials: Checkpoint Inhibitor, open to volunteers
Breast Cancer, Hematologic Malignancy
Global Cardio Oncology Registry
G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational, multicenter prospective observational cohort registry, with the goal of collecting clinical, laboratory, imaging, demographic, and…
- Conditions
- Breast Cancer, Hematologic Malignancy, Immune Checkpoint Inhibitor-Related Myocarditis, Cardiotoxicity
- Trial name
- G-COR (NCT05598879)
- Testing
- anonymized data collection during programmed surveillance clinical follow up
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- The Cleveland Clinic
HIV, AIDS
Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDS
This prospective, single-arm, open-label study aims to evaluate the efficacy and safety of a PD-1 inhibitor (Sintilimab) combined with standard anti-infective therapy in patients with advanced HIV disease (AHD) who are suffering…
- Conditions
- HIV, AIDS, Immune Checkpoint Inhibitors, Refractory Opportunistic Infection
- Trial name
- NCT07579247
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Public Health Clinical Center
Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor
IC Plus Low-dose Radiation Plus Cadonilimab in LANPC
This is a multi-center, open-label, randomized controlled phase III clinical trial in primary diagnosed loco-regionally advanced nasopharyngeal carcinoma (NPC) patients.
- Conditions
- Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy
- Trial name
- NCT05941741
- Testing
- Intensity Modulated Radiation Therapy, Chemotherapy, Immune checkpoint inhibitor
- Where
- 3 sites in China
- Volunteers
- 380 people
- Sponsor
- Sun Yat-sen University
Lung Cancer, Venous Thromboembolism
Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
The purpose of this observational study is to explore the incidence, risk factors, and relationship with therapeutic outcomes of VTE (venous thromboembolism) and ATE (arterial thromboembolism) associated with immune checkpoint…
- Conditions
- Lung Cancer, Venous Thromboembolism, Arterial Thromboembolism, Immune Checkpoint Inhibitors (ICIs)
- Trial name
- NCT06950697
- Where
- 5 sites in China
- Volunteers
- 2,400 people
- Sponsor
- Beijing Chao Yang Hospital
Solid Cancers, Radiotherapy
Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
Lattice radiation therapy (LRT) is a spatially fractionated radiotherapy technique that creates alternating high - and low - dose areas within a tumor to enhance local control and reduce toxicity to surrounding tissues.
- Conditions
- Solid Cancers, Radiotherapy, Immune Checkpoint Inhibitor, Lung Cancer
- Trial name
- SFRT-IM-P2 (NCT07058948)
- Testing
- lattice radiation therapy
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Immune Checkpoint Inhibitor-Induced Dermatitis
JAK Inhibitors for Solid Malignant Tumor Patients With Refractory Immune Checkpoint Inhibitors-related Dermatitis
Currently, the principal strategy for immune checkpoint inhibitors (ICI)-related dermatitis include systemic use of corticosteroids, which can impair the efficacy of preceding ICIs treatment.
- Trial name
- NCT07530224
- Testing
- treated with JAK inhibitors orally for 28 days
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shixiu Wu
Progressive Multifocal Leukoencephalopathy, Immune Checkpoint Inhibitors
Observational Cohort Study of Chronic Viral Infection in the Central Nervous System
This research team intends to conduct a real-world cohort study of chronic CNS viral infections represented by PML, to evaluate whether administration of immune checkpoint inhibitors improves long-term outcomes in this patient…
- Trial name
- NCT07512518
- Testing
- Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Peking Union Medical College Hospital
Inflammatory Arthritis, Rare Auto-immune Diseases
Understanding of Rare Inflammatory Arthritis in Comparison to Classical Inflammatory Arthritis : Tissular Observations and Immune Infiltrate Characterization : the UTOPIC Project
The pathophysiology of certain inflammatory arthritides remains poorly understood, particularly when associated with rare systemic autoimmune diseases such as systemic sclerosis (SSc), or when emerging in the context of…
- Conditions
- Inflammatory Arthritis, Rare Auto-immune Diseases, Immune Checkpoint Inhibitor Related Inflamamtory Arthritis
- Trial name
- UTOPIC (NCT07302074)
- Testing
- Biopsy
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Brest
Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
The CR1STAL-Adaptive study is a randomized, open-label, phase II multicenter interventional trial designed to evaluate the safety and efficacy of Ivonescimab (PD-1/VEGF bispecific antibody) combined with docetaxel versus standard…
- Trial name
- NCT06951646
- Testing
- Ivonescimab, Docetaxel, Standard Treatment group
- Where
- 20 sites in China
- Volunteers
- 70 people
- Sponsor
- Second Xiangya Hospital of Central South University
Checkpoint Inhibitor-related Pneumonitis
Diagnostic Biomarkers for Checkpoint Inhibitor-related Pneumonitis
Checkpoint inhibitor-related pneumonitis (CIP) is a common fatal immune-related adverse events of PD-1/PD-L1 inhibitors. Early diagnosis of CIP is crucial for timely intervention and improved prognosis; however, the absence of…
- Trial name
- NCT07340892
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhou Chengzhi
HCC, Adjuvant Therapy
Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma
Early hepatocellular carcinoma (HCC) recurrence (driven by residual tumors) and late recurrence (driven by de novo tumors) exhibit distinct biological behaviors, suggesting differential therapeutic vulnerabilities.
- Conditions
- HCC, Adjuvant Therapy, Recurrence, Immune Checkpoint Inhibitor
- Trial name
- NCT07379489
- Testing
- PD-1 Inhibitors
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Non Small Cell Lung Cancer, Breast Cancer
Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.
This is an observational clinical trial, aiming to investigate whether the ctDNA dynamics could predict early response to ICIs in patients with advanced-stage cancer.
- Conditions
- Non Small Cell Lung Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- PTC-IMPACT (NCT06227728)
- Where
- 2 sites in Vietnam
- Volunteers
- 50 people
- Sponsor
- Gene Solutions
Immune Checkpoint Inhibitor-Related Myocarditis
Monitoring and Rehabilitation for ICIACI Rehabilitation：A Cohort Study
Immune checkpoint inhibitor-associated cardiac injury (ICIACI) is a low-incidence but highly fatal adverse event. A significant knowledge gap exists regarding the disease characteristics and recovery status of patients during the…
- Trial name
- NCT07278817
- Volunteers
- 340 people
- Sponsor
- China-Japan Friendship Hospital
Immune Checkpoint Inhibitors Related Myocarditis
ICIAM Rehabilitation Program Study: A Randomized Controlled Trial
Immunotherapy has become a cornerstone in oncology; however, managing its associated adverse events poses a significant clinical challenge.
- Trial name
- NCT07280429
- Testing
- rehabilitation protocol
- Volunteers
- 60 people
- Sponsor
- China-Japan Friendship Hospital
Solid Cancer, Lymphopenia
PRaG-1 Plus PRaG Therapy in Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)
The goal of this clinical trial is to learn if a combination treatment using PRaG-1 Cordycepin Tablets with radiation therapy, immune-boosting injections, and immunotherapy drugs can help patients with advanced solid tumors.
- Conditions
- Solid Cancer, Lymphopenia, Radiotherapy, Immune Checkpoint Inhibitor
- Trial name
- NCT07267234
- Testing
- PD -1/PD-L1 monoclonal antibody
- Volunteers
- 65 people
- Sponsor
- Second Affiliated Hospital of Soochow University
Immune Checkpoint Inhibitor-Related Colitis
Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial
The goal of this clinical trial is to compare the effectiveness and safety of Vedolizumab with a short course of steroids compared to standard course of steroids for the treatment of immune checkpoint inhibitor colitis (ICI…
- Trial name
- EVITA (NCT06841705)
- Testing
- Vedolizumab 300 MG Injection [Entyvio], Prednisone (and methylprednisolone), Prednisone Taper
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Shilpa Grover, MD, MPH
Immune Checkpoint Inhibitors (ICI)-Related Dermatitis
JAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa Trial
Currently, the principal strategy for immune checkpoint inhibitors (ICI)-related dermatitis include systemic use of corticosteroids, which can impair the efficacy of preceding ICIs treatment.
- Trial name
- NCT06715982
- Testing
- JAK Inhibitor
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shixiu Wu
Pain Management, Immune Checkpoint Inhibitor
Study on the Relationship Between Opioid Drugs and the Therapeutic Efficacy of Immunotherapy
Relationship between pain and the efficacy of immunotherapy: Does the degree of pain control affect the therapeutic efficacy of ICIs? Does the use of opioid drugs independently affect the efficacy of immunotherapy?
- Conditions
- Pain Management, Immune Checkpoint Inhibitor, Opioid
- Trial name
- NCT07188857
- Volunteers
- 100 people
- Sponsor
- Hubei Cancer Hospital
Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
This study is an open-label, randomized controlled, multicenter, phase III clinical trial
- Conditions
- Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant, Immune Checkpoint Inhibitor, TACE
- Trial name
- NCT07186621
- Testing
- Sintilimab, radiotherapy, TACE
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Biliary Tract Cancer, Disitamab Vedotin
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
This trial is a single-arm exploratory phase II clinical study initiated by the investigator. Subjects who met the research criteria were screened and enrolled to receive the treatment regimen of disitamab vedotin combined with…
- Conditions
- Biliary Tract Cancer, Disitamab Vedotin, Lenvatinib, Immune Checkpoint Inhibitors
- Trial name
- NCT07159217
- Testing
- Disitamab Vedotin, Lenvatinib, Pembrolizumab
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Peking Union Medical College Hospital